2020 has been an incredibly challenging year for most of the world with seemingly very few bright spots to focus on. The emergence of COVID-19 has dramatically altered the way we live, perhaps permanently. Coronavirus-motivated mask mandates, regional shutdowns, capacity restrictions, and social distancing brought about economic uncertainty. The most commonly cited hope for a return to normalcy has been the widespread availability of a vaccine. Due to the fast-tracking of vaccine trials and significant government support, several effective vaccines appear to be on the horizon as we head into 2021.
The public health benefit is straight-forward, however the economy is a very important concern to many. Anticipating the vast impact across the economy is incredibly difficult due to the unpredictability of consumer confidence in the midst of the pandemic. Despite this unpredictability, the sizable economic impact of investment in the vaccine manufacturing process can be readily estimated with Input-Output Analysis. Using publicly available data to define input values, IMPLAN has performed an analysis of the effect of the Federal government’s spending on vaccine manufacturing.